Northwest & Ethical Investments L.P. Acquires 57,331 Shares of Bristol-Myers Squibb (NYSE:BMY)

Northwest & Ethical Investments L.P. raised its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 354.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,499 shares of the biopharmaceutical company's stock after acquiring an additional 57,331 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in Bristol-Myers Squibb were worth $4,157,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of BMY. Raymond James Financial Inc. bought a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $257,618,000. FMR LLC raised its holdings in shares of Bristol-Myers Squibb by 10.5% during the third quarter. FMR LLC now owns 44,940,609 shares of the biopharmaceutical company's stock valued at $2,325,227,000 after acquiring an additional 4,275,787 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Bristol-Myers Squibb by 695.1% in the third quarter. Janus Henderson Group PLC now owns 3,554,758 shares of the biopharmaceutical company's stock worth $183,971,000 after acquiring an additional 3,107,672 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Bristol-Myers Squibb by 18.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,074,823 shares of the biopharmaceutical company's stock worth $986,931,000 after acquiring an additional 3,002,418 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Bristol-Myers Squibb by 3.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 61,030,403 shares of the biopharmaceutical company's stock valued at $3,157,713,000 after acquiring an additional 1,968,729 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Stock Down 3.0 %

NYSE BMY traded down $1.83 during mid-day trading on Tuesday, reaching $59.22. The stock had a trading volume of 10,965,694 shares, compared to its average volume of 12,176,463. The company has a fifty day moving average price of $58.29 and a 200 day moving average price of $56.05. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The stock has a market cap of $120.18 billion, a PE ratio of -13.40, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.19%. Bristol-Myers Squibb's payout ratio is -56.11%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BMY shares. Bank of America reaffirmed a "neutral" rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Truist Financial upped their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and increased their price objective for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.